It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2015
  5. Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism

December 7, 2015

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism

Otsuka Pharmaceutical Co., Ltd. has submitted an application for regulatory approval in Japan of the anti-psychotic drug ABILIFY (generic name is aripiprazole) for the additional indication of excitability associated with autistic disorder for juveniles from ages 6 through 17. The proposed dosage form for the indication is ABILIFY Tablets, 1mg.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases